VBVéronique Baudouin

Véronique Baudouin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Véronique Baudouin has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement

    by Charlotte Duneton, Theresa Kwon, Claire Dossier, Veronique Baudouin, Marc Fila, Patricia Mariani-Kurkdijan, Isabelle Nel, Olivia Boyer, Julien Hogan

    Background Neurological complications pose a significant threat in pediatric hemolytic and uremic syndrome (HUS) resulting from infections with Shiga toxin-producing Escherichia coli (STEC), with no established treatment. The involvement of complement activation in the pathogenesis of STEC-HUS is acknowledged, and eculizumab (ECZ), a terminal complement blocker, has been documented in several pediatric series with inconsistent results. Antibody-mediated mechanisms have also been suggested, with IgG-immunoadsorption (IgIA) showing promise in adults with neurological complications. We aimed to assess the benefit of combining IgIA with ECZ in pediatric patients with neurological STEC-HUS compared to patients treated with ECZ alone or supportive care. Methods Multicenter retrospective study conducted on pediatric patients (< 18 years) with neurological STEC-HUS treated with IgIA + ECZ or ECZ alone from 2010 to 2020 in France. A historical cohort treated with supportive care served as controls. Primary outcome included survival and neurological evaluation at 1-year follow-up (dichotomized as normal vs. abnormal). Results A total of 42 children were included: 18 treated with IgIA + ECZ, 24 with ECZ alone, and 27 with supportive care. Although there was no significant difference in survival between groups, three deaths occurred in the control group in the acute phase, while none was reported in both the IgIA + ECZ and ECZ alone groups, despite presenting with more severe neurological symptoms for IgIA + ECZ patients. No significant association was found between treatment group and 1-year neurological evaluation after adjustment for age, sex, and initial neurological presentation. Conclusions Systematic association of IgIA + ECZ is not supported for all neurological STEC-HUS pediatric patients; potential rescue therapy for severe cases warrants consideration. Graphical Abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Top Cited Papers

    Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children

    by Claire Dossier, Stéphanie Bonneric, Véronique Baudouin, Thérésa Kwon, Benjamin Prim, Alexandra Cambier, Anne Couderc, Christelle Moreau, Georges Deschenes, Julien Hogan

    Background: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys. Methods: We retrospectively report 41 children with steroid-dependent or frequently relapsing nephrotic syndrome treated with a single low-dose infusion of obinutuzumab at Robert-Debre Hospital between April 2018 and December 2020. Participants were treated because of rituximab resistance or relapse after rituximab and received a single infusion of 300 mg/1.73 m2 obinutuzumab with cessation of oral immunosuppressors within 2 months. Results: B-cell depletion was achieved in all participants and lasted a median of 8.3 months (interquartile range, 6.4–11.1), a duration exceeding that for last rituximab treatment. At 12 and 24 months, 92% (38/41) and 68% (28/41) of patients, respectively, were in sustained remission. Mild infusion reactions occurred in five participants (12%) and neutropenia in nine (21%). No significant decrease in IgG level was reported during treatment, and whereas IgM levels decreased in 34 patients (83%), they were normal at last follow-up in 32 (78%). Conclusions: These results identified low-dose obinituzumab as a promising treatment option in children with steroid-dependent or frequently relapsing nephrotic syndrome, including those resistant to rituximab. The tolerance profile of obinutuzumab was similar to that of rituximab, but hemogram and immunoglobulin levels should be monitored.


  • Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN

    by Marie Sophie Meuleman, Paula Vieira-Martins, Carine El Sissy, Vincent Audard, Véronique Baudouin, Dominique Bertrand, Frank Bridoux, Férielle Louillet, Claire Dossier, Vincent Esnault, et al.

    Background: C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described. Methods: Three hundred ninety-eight patients with C3 glomerulopathy (n=296) or Ig-MPGN (n=102) from a national registry were screened for three complement genes: factor H (CFH), factor I (CFI), and C3. Patients with rare variant (minor allele frequency CFH, CFI, and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI, respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19–104) months, compared with 28% (55/195) after a median delay of 34 (12–143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases. Conclusions: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH, CFI, or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3


  • Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case

    by Alexandra Cambier, Claire Dossier, Julien Hogan, Véronique Baudouin, Anne Maisin, Anne Couderc, Theresa Kwon, Patrick J. Gleeson, Renato C. Monteiro

    Background Childhood IgA nephropathy (cIgAN) is one of the most common primary glomerulonephritides with the potential to evolve to kidney failure. IgAN is an autoimmune disease involving 3 key factors: galactose-deficient IgA1 (Gd-IgA1), anti-IgA1 autoantibodies, and soluble (s)CD89 IgA Fc receptor. These molecules and immune complexes have been described recently as potential biomarkers of disease progression in childhood IgAN but their evolution in time under immunosuppressive treatment remains unknown. Methods We performed a prospective study of two proliferative cIgAN patients by sequentially biomonitoring immune IgA complexes (sCD89-IgA, IgG-IgA), sCD89, and Gd-IgA1 and correlating them with clinical and histological outcome after treatment. Results After patient 1’s treatment, a decrease in sCD89-IgA, IgG-IgA, and free sCD89 was linked to a decrease in proteinuria whereas eGFR (estimated glomerular filtration rate) and Gd-IgA1 levels remained stable. Patient 1 received tacrolimus and monthly intramuscular steroid injections of Kenacort for 10 months. At the end, a relapse induced an increase in proteinuria consistent with an increase of the 3 biomarkers. Patient 2 displayed rapidly progressive IgAN with crescents in more than 90% of glomeruli and received intense immunosuppression treatment associated with the immunoadsorption (IA) approach. During IA, proteinuria decreased rapidly, as well as levels of CD89-IgA, IgG-IgA, sCD89, and Gd-IgA1 biomarkers. After discontinuation of IA, proteinuria increased as well as IgG-IgA complexes whereas sCD89-IgA and sCD89 remained low. Further re-intensification of IA and addition of cyclophosphamide improved proteinuria again with reduced IgG-IgA. A second biopsy was performed showing a reduction of extracapillary proliferation to 6% of glomeruli and only 9% glomerulsoclerosis. Conclusions In conclusion, sequential biomonitoring of Gd-IgA1, IgA-immune complexes, and sCD89 in cIgAN was found to be valuable, by correlating with clinical features and glomerular proliferative lesions in cIgAN. These biomarkers could represent useful tools to evaluate kidney injury without repeat kidney biopsies.


  • Lung manifestations in MPO‐ANCA associated vasculitides in children

    by Salma Ben Ameur, Patrick Niaudet, Véronique Baudouin, Muriel Le. Bourgeois, Véronique Houdouin, Christophe Delacourt, Alice Hadchouel

    Objective: To describe lung manifestations in MPO‐ANCA associated vasculitides in children.Methods: We retrospectively reviewed the medical records of patients with MPO‐ANCA associated vasculitis, who were followed in two pediatric nephrology departments from January 2000 to December 2010.Results: Twelve patients were identified with MPO‐ANCA over the study period. Their median age (IQR) at diagnosis was 10.5 (6.3–12.0) years, and their median duration of follow‐up was 4.8 (1.2–7.5) years. Only five of them had pulmonary involvement with diffuse alveolar hemorrhage. Lung involvement was inaugural for four of five children. One child with severe chronic respiratory disease and renal failure died after 6 years of disease progression. Pulmonary function tests were available for 10 children. They were within normal ranges in four of five patients without clinical lung manifestations, and no significant impairment was observed in children with pulmonary complications.Conclusions: Diffuse alveolar hemorrhage complicates 40% of cases of MPO‐ANCA associated vasculitides in children with renal involvement. After an acute potentially severe phase, a complete recovery without significant functional impairment was observed in four of five affected children. Pediatr Pulmonol. 2014; 49:285–290.


  • Open Access

    Pathophysiology and clinical studies in CKD 1-5.

    by Magdy El Sharkawy, Kadry Elsaeed, Mostafa Kamel, Ahmed Aziz, Carlos Del Pozo, Anja Balk, Juan Castello-Banyuls, Daniela Navarro, Berbel Pere, Clara C. Faura, et al.

    INTRODUCTION AND AIMS: Gastrointestinal (GI) symptoms are common in patients with chronic renal failure (CRF), but the pathogenesis of these symptoms is unclear. Abnormal gastric motility disorders and esophageal motor dysfunctions are commonly described in uremic patients. The gastrointestinal disorders possibly affect function and structure of the gastrointestinal tract and negatively impact on the nutritional status of the patients causing malnutrition which is a major problem with ESRD.

  • Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients

    by Wei Zhao, Véronique Baudouin, Daolun Zhang, Georges Deschênes, Chantal Le Guellec, Evelyne Jacqz-Aigrain

    Objective: To develop a population pharmacokinetic model for valganciclovir in paediatric renal transplant recipients, identify covariates that explain variability, and determine valganciclovir dosage regimens for cytomegalovirus (CMV) prophylaxis in children. Methods: The pharmacokinetics of valganciclovir were described with plasma concentrations from 22 patients (age range 3–17 years) using nonlinear mixed-effects modelling (NONMEM) software. A two-compartment model with lag-time and first-order absorption and elimination was developed. The final model was validated using a bootstrap and visual predictive check. The dosage regimens of valganciclovir for CMV prophylaxis in children were simulated using the final model. Results: The mean population pharmacokinetic parameters were apparent systemic clearance (CL) 10.1 L/h, apparent central volume of distribution 5.2 L, apparent peripheral volume of distribution 30.7 L, inter-tissue clearance 3.97 L/h, absorption rate constant 0.369 h−1 and lag-time 0.743 h. The covariate analysis identified creatinine clearance (CLCR) and bodyweight (WT) as individual factors influencing the apparent oral clearance: CL = 8.04 · (CLCR/89)2.93 + 3.62 · (WT/28) L/h. The results of the simulation showed that for a typical patient (WT 28 kg and CLCR 89 mL/min), an area under the plasma concentration-time curve of 43 ± 10.6 mg · h/mL will be achieved with valganciclovir 500 mg once daily. Conclusion: The dosage regimens of valganciclovir for CMV prophylaxis have been defined using the final population pharmacokinetic model based on WT and CLCR for paediatric renal transplantation patients.